At-home Leqembi starting in 2026 does not change brain-MRI safety checks for people with mild cognitive impairment. Patients still need a baseline MRI plus regular surveillance scans to watch for ARIA, a brain swelling and bleeding risk linked to amyloid-clearing drugs. Eisai reports the FDA approved Leqembi Iqlik, once-weekly lecanemab-irmb, as a starting dose for early Alzheimer's on July 13, 2026, in the company approval notice. That change allows eligible patients to begin treatment at home instead of starting with clinic infusions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can start treatment with mild cognitive impairment
- How does at-home starting work
- Which MRI checks still apply
- What raises ARIA risk
Who can start treatment with mild cognitive impairment
Leqembi remains only for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. Eisai states these stages together count as early Alzheimer's.
Treatment must also start during that early stage. Confirmed amyloid pathology is also required. In practice this means a memory evaluation, an Alzheimer's diagnosis, and an amyloid test come before any prescription.
How does at-home starting work
The approved starting regimen is 500 mg once weekly as two 250-mg autoinjector injections of about 15 seconds each, according to Eisai and Biogen in the approval announcement. After 18 months, the dose changes to 360 mg once weekly for maintenance.
This is different from the earlier at-home option. The Alzheimer's Association reports the August 2025 approval covered weekly subcutaneous maintenance only for patients who had finished 18 months of IV treatment.
- confirm early Alzheimer's and amyloid status
- complete baseline MRI and ApoE testing
- train patient and caregiver on autoinjector use
- keep scheduled MRIs and clinician visits
Which MRI checks still apply
Medscape reports switching to home injections does not reduce safety monitoring. Baseline brain MRI, surveillance MRIs, caregiver training, and clinician oversight remain required for either IV or subcutaneous treatment.
FDA labeling calls for a recent baseline MRI plus MRIs before the 5th, 7th and 14th IV infusions. An August 28, 2025 FDA safety communication added an earlier MRI between the 2nd and 3rd infusions to find ARIA-E sooner, as described by the FDA in the safety update summary.
What raises ARIA risk
Leqembi carries a boxed warning because anti-amyloid antibodies can cause ARIA-E with brain swelling or fluid around the brain and ARIA-H with small bleeds or iron deposits. These events include serious and fatal bleeding inside the brain.
Risk is highest in ApoE e4 homozygotes, meaning people with two copies of that gene variant. An Eisai and Biogen safety summary reports ARIA in 45 percent of treated homozygotes versus 22 percent on placebo, with lower rates in others, in the safety summary. Prior tiny bleeds also raise risk, so genotyping and close vigilance during roughly the first 14 weeks are recommended.
You Might Also Like
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: What People With Mild Cognitive Impairment Should Know About the News
- The Long-Term Care Data Cooperative and Dementia Research in 2026: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
- Repetitive Heading and Brain Health Findings at AAIC 2026: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
